ArticleHarm reduction journal2025
Operational and clinical procedures of heroin-assisted treatment in Switzerland: a nation-wide survey study.
Article in Harm reduction journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Patterns of medical comorbidities among aging people receiving heroin-assisted treatment: A 10-year single-center repeated cross-sectional study.Drug and alcohol dependence reports · 2026Article
- Providers' perspectives on what heroin-assisted treatment ought to be: a qualitative study.BMC health services research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHeroin-assisted treatment (HAT) was introduced in Switzerland in 1994 and comprises the prescription of diacetylmorphine (DAM, heroin) for patients with severe opioid use disorder. Provision of Swiss HAT is limited to specialised treatment centres, 22 of which operate today. The aim of this study was to assess the characteristics and clinical procedures of these centres.
methodsA questionnaire was designed and sent out to all operating Swiss HAT centres.
resultsThe response rate was 91% and all questionnaires were filled in by the medical heads of the corresponding centres. All centres employed psychiatrists and prescribed psychiatric medication. Additionally, 85% reported to offer in-house psychotherapeutic treatment and 95% reported to employ social workers. Few treatment barriers to HAT were found, with the mean time from referral to treatment initiation being 10 days. Only one centre reported to employ a waiting list. Off-label prescriptions, including intramuscular and intranasal administrations, were common. All centres offered the concurrent prescription of methadone and slow-release oral morphine. Furthermore, all centres prescribed take-home DAM. However, vast differences among centres regarding DAM dosing and titration were found. No uniformly employed factors for converting DAM to other opioids exist across centres. Overdoses and seizures were reported to be very rare.
conclusionsSwiss HAT is overall easily accessible, patient-centred and safe for patients and staff. Some procedures are based on local tradition rather than on scientific evidence. Evidence-based treatment recommendations are needed to further improve quality of care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.